MNKD 2018 Proxy Statement

The following table summarizes the equity awards granted to the named executive officers during the fiscal year ended December 31, 2017. Grants of Plan-Based Awards in Fiscal 2017(1) Name Grant Date All Other Stock Awards: Number of Shares of Stock or Units (#)(2) All Other Option Awards: Number of Securities Underlying Options (#) Exercise or Base Price of Options Awards Options ($/Sh) Grant Date Fair Value of Stock and Option Awards ($) Michael E. Castagna, Pharm.D . . . . . . . . . . . . . 5/25/17 — 150,100(4) 1.42 151,076 5/29/17 — 191,000(3) 1.52 205,974 5/29/17 — 231,000(4) 1.52 249,110 Steven B. Binder . . . . . . . . . . . . . . . . . . . . . . . . 8/24/17 — 180,100(4) 1.47 190,204 Matthew J. Pfeffer . . . . . . . . . . . . . . . . . . . . . . . — — — — — Rosabel R. Alinaya . . . . . . . . . . . . . . . . . . . . . . 5/25/17 — 63,000(4) 1.42 63,410 5/29/17 — 50,000(4) 1.52 53,920 Stuart A. Tross . . . . . . . . . . . . . . . . . . . . . . . . . . 2/16/17 — 80,000(3) 2.70 148,640 2/16/17 — 80,000(4) 2.70 148,640 2/16/17 20,000 — 2.70 54,000 5/25/17 — 112,575(4) 1.42 113,307 David Thomson, Ph.D., J.D. . . . . . . . . . . . . . . . 5/25/17 — 150,100(4) 1.42 151,076 Joseph Kocinsky . . . . . . . . . . . . . . . . . . . . . . . . 5/25/17 — 150,100(4) 1.42 151,076 (1) All equity awards were granted under the 2013 Plan. (2) The shares subject to these restricted stock units vest annually over a four-year period. (3) The shares subject to these options have exercise prices equal to the fair market value of our common stock on the date of grant and vest over a four-year period with a one-year 25% cliff vesting and monthly thereafter over the following three years. These options expire ten years from the date of grant. Vesting ceases should the executive officer no longer provide continuous service to us. (4) The shares subject to these options will vest upon achievement of specified business development milestones related to quarterly product sales at an annualized rate. These options expire ten years from the date of grant. Reference Note 13 “Stock award plans” in the notes to our financial statements for the period ended December 31, 2017, included in Part IV, Item 15 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on February 27, 2018, which identifies the assumptions made in the valuation of equity awards in accordance with ASC 718. 57